Search research articles
Contact Us
Filters
Showing results (41-50 of 77) with videos related to
Page
of 8
Sort By:
Leukemia & Lymphoma
|
December 16, 2020
Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma
Edith Szafer-Glusman, Juan Liu, Arijit Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2023
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
Nitin Jain, Lisa J Croner, John N Allan, et al.
Development (Cambridge, England)
|
October 25, 2019
<i>Drosophila</i> Doublefault protein coordinates multiple events during male meiosis by controlling mRNA translation
Stefano Sechi, Anna Frappaolo, Angela Karimpour-Ghahnavieh, et al.
American Journal of Hematology
|
March 2, 2017
BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab
Sarah Huet, Edith Szafer-Glusman, Bruno Tesson, et al.
Oncotarget
|
February 18, 2017
Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients
Marius Ilie, Edith Szafer-Glusman, Véronique Hofman, et al.
Blood
|
July 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
Jan A Burger, Paul M Barr, Tadeusz Robak, et al.
Blood Advances
|
July 10, 2026
MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL
Isil Altintas, Christopher Morehouse, Elena Favaro, et al.
Blood Advances
|
May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
Maissa Mhibik, Erika M Gaglione, David Eik, et al.
Ebiomedicine
|
June 25, 2018
Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies
Peng-Peng Xu, Chun Sun, Xu Cao, et al.
Leukemia & Lymphoma
|
June 18, 2025
Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma
Durga B Dandamudi, Iwona M Konieczna, Kelly M Calabrese, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 77) with videos related to
Sort By:
Page
of 8
Leukemia & Lymphoma
|
December 16, 2020
Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma
Edith Szafer-Glusman, Juan Liu, Arijit Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2023
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
Nitin Jain, Lisa J Croner, John N Allan, et al.
Development (Cambridge, England)
|
October 25, 2019
<i>Drosophila</i> Doublefault protein coordinates multiple events during male meiosis by controlling mRNA translation
Stefano Sechi, Anna Frappaolo, Angela Karimpour-Ghahnavieh, et al.
American Journal of Hematology
|
March 2, 2017
BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab
Sarah Huet, Edith Szafer-Glusman, Bruno Tesson, et al.
Oncotarget
|
February 18, 2017
Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients
Marius Ilie, Edith Szafer-Glusman, Véronique Hofman, et al.
Blood
|
July 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
Jan A Burger, Paul M Barr, Tadeusz Robak, et al.
Blood Advances
|
July 10, 2026
MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL
Isil Altintas, Christopher Morehouse, Elena Favaro, et al.
Blood Advances
|
May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
Maissa Mhibik, Erika M Gaglione, David Eik, et al.
Ebiomedicine
|
June 25, 2018
Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies
Peng-Peng Xu, Chun Sun, Xu Cao, et al.
Leukemia & Lymphoma
|
June 18, 2025
Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma
Durga B Dandamudi, Iwona M Konieczna, Kelly M Calabrese, et al.
Page
of 8